Friday 16 October 2026
Export ALEC’s income statement to Excel — free account
Alector, Inc.
ALEC Healthcare Biotechnology
Alector, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $21.0 million, down 79.1% from fiscal 2024. In the quarter to June 2026, revenue fell 57.8%, EPS grew 30.0%, free cash flow grew 30.2% and total debt rose 3.27%, each against the same quarter a year earlier.
1.84
0.07
−3.66%
Follow ALEC
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
4.40 | 7.64 | 12.91 | 16.13 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(9.34) | (3.85) | (4.77) | (6.53) | |
P/B ratio |
5.26 | 5.24 | 22.90 | 0.00 | |
Price to Tangible BV |
5.26 | 5.24 | 22.90 | 0.00 | |
EV/Sales |
0.44 | (4.07) | 2.23 | 4.97 | |
EV/EBITDA |
0.00 | 0.56 | 0.00 | 0.00 | |
EV/Operating CF |
(0.15) | 0.47 | (0.24) | (0.44) | |
EV/FCF |
(0.15) | 0.47 | (0.24) | (0.43) | |
Quick Ratio |
3.64 | 3.68 | 5.04 | 5.05 | |
Current Ratio |
3.76 | 3.83 | 5.25 | 5.26 | |
Net Debt/EBITDA |
7.66 | 6.40 | 8.40 | 7.16 | |
Debt/Assets |
2.87% | 3.30% | 4.07% | 4.85% | |
Debt/Equity |
0.17 | 0.32 | 0.94 | (0.99) | |
Asset Turnover |
0.16 | 0.06 | 0.06 | 0.05 | |
Operating CF/Net income |
0.94 | 1.12 | 2.17 | 1.49 | |
Capex/Depreciation |
(0.01) | 0.00 | (0.08) | (0.02) | |
Research and Development Expense of Revenue |
900.31% | 520.49% | 1,707.17% | 586.14% | |
Selling, General and Administrative Expense of Revenue |
353.31% | 213.88% | 775.14% | 248.58% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
196.38% | 77.65% | 278.01% | 78.61% | |
Graham Net Nets |
0.08 | 0.02 | (0.06) | (0.15) | |
Graham Number |
0.00 | 0.00 | 0.00 | 1.49 | |
Earnings Yield |
(36.15%) | (89.10%) | (55.35%) | (54.73%) | |
Free Cash Flow Yield |
(65.06%) | (114.56%) | (72.84%) | (70.85%) | |
Revenue per Share |
0.03 | 0.06 | 0.01 | 0.03 | |
Operating CF per Share |
(0.32) | (0.40) | (0.45) | (0.31) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.32) | (0.40) | (0.45) | (0.31) | |
Cash per Share |
2.84 | 2.49 | 1.87 | 1.55 | |
Shareholders Equity per Share |
0.56 | 0.30 | 0.09 | (0.09) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.56 | 0.30 | 0.09 | (0.09) | |
Free Cash Flow |
(32.52) | (41.69) | (49.93) | (34.25) | |
Working Capital |
220.42 | 196.95 | 174.12 | 145.85 | |
Capital Expenditures |
(0.01) | 0.00 | (0.12) | (0.03) | |
Net Current Asset Value |
22.81 | 3.86 | (14.45) | (32.74) | |
EV/EBIT |
0.00 | 0.55 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.11 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
4.89 | 1.95 | 1.87 | 2.25 | |
Average Assets |
425.65 | 380.77 | 324.11 | 279.64 | |
Average Common Equity |
88.32 | 78.72 | 52.50 | 30.60 |
Columns are period end dates